Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Equus caballus | Cholinesterase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma japonicum | ko:K01050 cholinesterase [EC3.1.1.8], putative | Cholinesterase | 574 aa | 577 aa | 36.9 % |
Brugia malayi | Carboxylesterase family protein | Cholinesterase | 574 aa | 538 aa | 31.4 % |
Onchocerca volvulus | Cholinesterase | 574 aa | 578 aa | 25.3 % | |
Onchocerca volvulus | Cholinesterase | 574 aa | 551 aa | 29.9 % | |
Echinococcus multilocularis | BC026374 protein (S09 family) | Cholinesterase | 574 aa | 636 aa | 34.9 % |
Brugia malayi | Carboxylesterase family protein | Cholinesterase | 574 aa | 549 aa | 29.5 % |
Onchocerca volvulus | Putative nuclear protein | Cholinesterase | 574 aa | 572 aa | 40.9 % |
Onchocerca volvulus | Galectin homolog | Cholinesterase | 574 aa | 531 aa | 39.7 % |
Echinococcus granulosus | BC026374 protein S09 family | Cholinesterase | 574 aa | 642 aa | 34.4 % |
Echinococcus multilocularis | neuroligin | Cholinesterase | 574 aa | 493 aa | 26.2 % |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | Cholinesterase | 574 aa | 590 aa | 25.1 % |
Echinococcus granulosus | neuroligin | Cholinesterase | 574 aa | 492 aa | 24.4 % |
Loa Loa (eye worm) | hypothetical protein | Cholinesterase | 574 aa | 520 aa | 27.1 % |
Onchocerca volvulus | Molybdopterin synthase catalytic subunit homolog | Cholinesterase | 574 aa | 560 aa | 29.3 % |
Onchocerca volvulus | Carnitine O-palmitoyltransferase 2, mitochondrial homolog | Cholinesterase | 574 aa | 554 aa | 36.1 % |
Drosophila melanogaster | CG10175 gene product from transcript CG10175-RE | Cholinesterase | 574 aa | 547 aa | 29.4 % |
Brugia malayi | Carboxylesterase family protein | Cholinesterase | 574 aa | 472 aa | 27.5 % |
Onchocerca volvulus | Cholinesterase | 574 aa | 586 aa | 27.1 % | |
Loa Loa (eye worm) | hypothetical protein | Cholinesterase | 574 aa | 573 aa | 26.4 % |
Schistosoma mansoni | gliotactin | Cholinesterase | 574 aa | 587 aa | 27.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Trichomonas vaginalis | tubulin alpha chain, putative | 0.0053 | 0.5302 | 1 |
Loa Loa (eye worm) | BEN-1 protein | 0.0053 | 0.5302 | 0.5302 |
Trichomonas vaginalis | tubulin epsilon chain, putative | 0.0053 | 0.5302 | 1 |
Trypanosoma brucei | beta tubulin | 0.0053 | 0.5302 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Trypanosoma brucei | beta tubulin | 0.0053 | 0.5302 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Echinococcus multilocularis | beta tubulin | 0.0053 | 0.5302 | 0.5302 |
Entamoeba histolytica | tubulin family protein | 0.0053 | 0.5302 | 1 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Trypanosoma brucei | beta tubulin | 0.0053 | 0.5302 | 1 |
Toxoplasma gondii | beta-tubulin, putative | 0.0053 | 0.5302 | 1 |
Schistosoma mansoni | tubulin subunit beta | 0.0053 | 0.5302 | 0.5302 |
Echinococcus granulosus | tubulin beta 1 chain | 0.0053 | 0.5302 | 0.5302 |
Schistosoma mansoni | tubulin subunit beta | 0.0053 | 0.5302 | 0.5302 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Loa Loa (eye worm) | tubulin beta-4 chain | 0.0053 | 0.5302 | 0.5302 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Trichomonas vaginalis | tubulin, putative | 0.0053 | 0.5302 | 1 |
Echinococcus multilocularis | beta tubulin | 0.0053 | 0.5302 | 0.5302 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Loa Loa (eye worm) | beta-tubulin | 0.0053 | 0.5302 | 0.5302 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 1 | 1 |
Toxoplasma gondii | beta tubulin | 0.0053 | 0.5302 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0082 | 1 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Loa Loa (eye worm) | tubulin beta chain | 0.0053 | 0.5302 | 0.5302 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0082 | 1 | 1 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Echinococcus multilocularis | tubulin, beta 4A class IVa | 0.0053 | 0.5302 | 0.5302 |
Echinococcus granulosus | acetylcholinesterase | 0.0082 | 1 | 1 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Echinococcus multilocularis | tubulin beta 1 chain | 0.0053 | 0.5302 | 0.5302 |
Trypanosoma brucei | beta tubulin | 0.0053 | 0.5302 | 1 |
Loa Loa (eye worm) | tubulin beta-2A chain | 0.0053 | 0.5302 | 0.5302 |
Plasmodium vivax | tubulin beta chain, putative | 0.0053 | 0.5302 | 1 |
Trichomonas vaginalis | tubulin epsilon chain, putative | 0.0053 | 0.5302 | 1 |
Trypanosoma cruzi | beta tubulin, putative | 0.0053 | 0.5302 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Trichomonas vaginalis | tubulin beta chain, putative | 0.0053 | 0.5302 | 1 |
Trichomonas vaginalis | tubulin gamma chain, putative | 0.0053 | 0.5302 | 1 |
Schistosoma mansoni | tubulin subunit beta | 0.0053 | 0.5302 | 0.5302 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0082 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0082 | 1 | 1 |
Toxoplasma gondii | beta-1 tubulin, putative | 0.0053 | 0.5302 | 1 |
Echinococcus granulosus | tubulin subunit beta | 0.0053 | 0.5302 | 0.5302 |
Echinococcus multilocularis | tubulin subunit beta | 0.0053 | 0.5302 | 0.5302 |
Loa Loa (eye worm) | tubulin beta-1 chain | 0.0053 | 0.5302 | 0.5302 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Plasmodium falciparum | tubulin beta chain | 0.0053 | 0.5302 | 1 |
Giardia lamblia | Beta tubulin | 0.0053 | 0.5302 | 1 |
Giardia lamblia | Beta tubulin | 0.0053 | 0.5302 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Giardia lamblia | Beta tubulin | 0.0053 | 0.5302 | 1 |
Schistosoma mansoni | tubulin subunit beta | 0.0053 | 0.5302 | 0.5302 |
Brugia malayi | beta-tubulin, identical | 0.0053 | 0.5302 | 0.5302 |
Schistosoma mansoni | tubulin subunit beta | 0.0053 | 0.5302 | 0.5302 |
Echinococcus granulosus | beta tubulin | 0.0053 | 0.5302 | 0.5302 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Echinococcus multilocularis | acetylcholinesterase | 0.0082 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.0082 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0082 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0082 | 1 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Echinococcus granulosus | tubulin beta 4A class IVa | 0.0053 | 0.5302 | 0.5302 |
Loa Loa (eye worm) | BEN-1 protein | 0.0053 | 0.5302 | 0.5302 |
Entamoeba histolytica | tubulin family protein | 0.0053 | 0.5302 | 1 |
Schistosoma mansoni | tubulin subunit beta | 0.0053 | 0.5302 | 0.5302 |
Echinococcus granulosus | beta tubulin | 0.0053 | 0.5302 | 0.5302 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Leishmania major | beta tubulin | 0.0053 | 0.5302 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.0082 | 1 | 1 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0053 | 0.5302 | 0.5302 |
Brugia malayi | Tubulin beta-1 chain | 0.0053 | 0.5302 | 0.5302 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 13.6 % | Neuroprotective activity against amyloid beta 1 to 42-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 3 uM pre-incubated for 24 hrs before amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 14.7 % | Antioxidant activity in human SH-SY5Y cells assessed as sequestering of rotenone/oligomycin A-induced mitochondrial free radicals at 0.3 uM after 120 mins by DCFH-DA assay | ChEMBL. | 21420206 |
Activity (functional) | = 28.3 % | Neuroprotective activity against okadaic acid-induced cell death in human SH-SY5Y cells assessed as LDH release at 0.3 uM treated 24 hrs before okadaic acid challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 28.6 % | Neuroprotective activity against rotenone/oligomycin A-induced cell death in human SH-SY5Y cells assessed as LDH release at 0.3 uM after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 29 % | Neuroprotective activity against okadaic acid-induced cell death in human SH-SY5Y cells assessed as LDH release at 3 uM treated 24 hrs before okadaic acid challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 32 % | Neuroprotective activity against okadaic acid-induced cell death in human SH-SY5Y cells assessed as LDH release at 1 uM treated 24 hrs before okadaic acid challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 34.6 % | Neuroprotective activity against FPL64176-induced toxicity in human SH-SY5Y cells assessed as increase in cell viability at 3 uM treated 24 hrs before FPL64176 challenge measured after 24 hrs by MTT assay relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 36.3 % | Neuroprotective activity against FPL64176-induced toxicity in human SH-SY5Y cells assessed as increase in cell viability at 10 uM treated 24 hrs before FPL64176 challenge measured after 24 hrs by MTT assay relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 39.8 % | Neuroprotective activity against FPL64176-induced toxicity in human SH-SY5Y cells assessed as increase in cell viability at 0.3 uM treated 24 hrs before FPL64176 challenge measured after 24 hrs by MTT assay relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 44.1 % | Neuroprotective activity against rotenone/oligomycin A-induced cell death in human SH-SY5Y cells assessed as LDH release at 1 uM after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 44.3 % | Neuroprotective activity against rotenone/oligomycin A-induced cell death in human SH-SY5Y cells assessed as LDH release at 3 mM after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 44.5 % | Neuroprotective activity against FPL64176-induced toxicity in human SH-SY5Y cells assessed as increase in cell viability at 1 uM treated 24 hrs before FPL64176 challenge measured after 24 hrs by MTT assay relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 51.8 % | Neuroprotective activity against rotenone/oligomycin A-induced cell death in human SH-SY5Y cells assessed as LDH release at 1 uM treated 24 hrs before rotenone/oligomycin A challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 54.6 % | Neuroprotective activity against H2O2-induced cell death in human SH-SY5Y cells assessed as LDH release at 1 uM incubated for 24 hrs before H2O2 challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 55 % | Neuroprotective activity against rotenone/oligomycin A-induced cell death in human SH-SY5Y cells assessed as LDH release at 0.3 uM treated 24 hrs before rotenone/oligomycin A challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 57.7 % | Neuroprotective activity against H2O2-induced cell death in human SH-SY5Y cells assessed as LDH release at 3 uM incubated for 24 hrs before H2O2 challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 58.9 % | Neuroprotective activity against rotenone/oligomycin A-induced cell death in human SH-SY5Y cells assessed as LDH release at 3 uM treated 24 hrs before rotenone/oligomycin A challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 69.5 % | Neuroprotective activity against H2O2-induced cell death in human SH-SY5Y cells assessed as LDH release at 30 uM incubated for 24 hrs before H2O2 challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 79.9 % | Neuroprotective activity against H2O2-induced cell death in human SH-SY5Y cells assessed as LDH release at 10 uM incubated for 24 hrs before H2O2 challenge measured after 24 hrs relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 81.3 % | Neuroprotective activity against amyloid beta 1 to 42-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 1 uM pre-incubated for 24 hrs before amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control | ChEMBL. | 21420206 |
Activity (functional) | = 91.3 % | Neuroprotective activity against amyloid beta 1 to 42-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 0.3 uM pre-incubated for 24 hrs before amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control | ChEMBL. | 21420206 |
IC50 (binding) | = 1 uM | Inhibition of BuChE in horse serum using butyrylthiocholine as substrate by Ellman method | ChEMBL. | 21420206 |
IC50 (binding) | > 100 uM | Inhibition of AChE in bovine erythrocytes using acetylthiocholine as substrate by Ellman method | ChEMBL. | 21420206 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.